Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul:144:155585.
doi: 10.1016/j.metabol.2023.155585. Epub 2023 May 6.

Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes

Affiliations
Review

Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes

Yoshitaka Hashimoto et al. Metabolism. 2023 Jul.

Abstract

Diabetes prevalence is increasing rapidly in older people, and sarcopenia is prevalent as a novel complication, particularly in patients with type 2 diabetes mellitus (T2DM). Therefore, sarcopenia prevention and treatment in these people is necessary. Diabetes accelerates sarcopenia through several mechanisms, such as hyperglycemia, chronic inflammation and oxidative stress. The effects of diet, exercise, and pharmacotherapy on sarcopenia in patients with T2DM need to be considered. In diet, low intake of energy, protein, vitamin D, and ω-3 fatty acid are associated with sarcopenia risk. In exercises, although intervention studies in people, especially older and non-obese patients with diabetes, are few, accumulating evidence shows the usefulness of exercise, particularly resistance exercise for muscle mass and strength, and aerobic exercise for physical performance in sarcopenia. In pharmacotherapy, certain classes of anti-diabetes compounds have possibility of preventing sarcopenia. However, much data on diet, exercise, and pharmacotherapy were obtained in obese and non-elderly patients with T2DM, demanding actual clinical data on non-obese and older patients with diabetes.

Keywords: Aged; Diabetes; Diets; Exercise; Lifestyles; Medication; Muscle mass; Older; Sarcopenia.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Hashimoto reports personal fees from Novo Nordisk Pharma Ltd., Sanofi K.K., Mitsubishi Tanabe Pharma Corp., Ono Pharma Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Kowa Pharma Co. Ltd., and Sumitomo Dainippon Pharma Co. Ltd. Dr. Hamaguchi received grants from Daiichi Sankyo Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corp., Novo Nordisk Pharma Ltd., Sanofi K.K., Takeda Pharma Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Asahi Kasei Pharma, Kyowa Kirin Co. Ltd., and Eli Lilly Japan K.K. outside the submitted work. Prof. Fukui received grants from Taisho Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corp, Novo Nordisk Pharma Ltd., Ono Pharma Co. Ltd., Kowa Pharma Co. Ltd., Sanofi K.K., Nippon Boehringer Ingelheim Co. Ltd., Daiichi Sankyo Co. Ltd., Kissei Pharma Co. Ltd., MSD K.K., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly Japan K.K., Tejin Pharma Ltd., Takeda Pharma Co. Ltd., Nippon Chemiphar Co., Ltd., Astellas Pharma Inc., Abbott Japan Co. Ltd., Sanwa Kagagu Kenkyusho CO., LtD., Johnson & Johnson k.k. Medical Co., and Terumo Corp., and received honoraria from AstraZeneca K.K., Taisho Pharma Co., Ltd., Ono Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Sanofi K.K., Teijin Pharma Ltd., Takeda Pharma Co. Ltd., Astellas Pharma Inc., MSD K.K., Mitsubishi Tanabe Pharma Corp., Eli Lilly Japan K.K., Kissei Pharma Co., Ltd., Sumitomo Dainippon Pharma Co. Ltd., Daiichi Sankyo Co. Ltd., Mochida Pharma Co. Ltd., Kowa Pharma Co. Ltd., Arkray Inc., Abbott Japan Co. Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., Kyowa Kirin Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., Medtronic Japan Co. Ltd., Bayer Yakuhin, Ltd., and Nipro Corp. outside the submitted work. The other authors declare no conflict of interest.

Publication types

LinkOut - more resources